Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame

被引:45
|
作者
Parker, Edward P. K. [1 ]
Molodecky, Natalie A. [1 ]
Pons-Salort, Margarita [1 ]
O'Reilly, Kathleen M. [1 ]
Grassly, Nicholas C. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England
基金
英国医学研究理事会; 比尔及梅琳达.盖茨基金会; 英国惠康基金;
关键词
environmental surveillance; eradication; inactivated poliovirus vaccine; mucosal immunity; oral poliovirus vaccine; poliovirus; PREEXISTING HOMOTYPIC ANTIBODIES; QUANTITATIVE RELATIONSHIP; ROUTINE IMMUNIZATION; INTESTINAL IMMUNITY; HOUSEHOLD CONTACTS; IMMUNOGLOBULIN-A; LIVE VIRUS; POLIOMYELITIS; EXCRETION; IMMUNOGENICITY;
D O I
10.1586/14760584.2015.1052800
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized that inactivated poliovirus vaccine (IPV) is incapable of inducing a strong mucosal response on its own, it has recently become clear that IPV may boost immunity in the intestinal mucosa among individuals previously immunized with oral poliovirus vaccine. Indeed, mucosal protection appears to be stronger following a booster dose of IPV than oral poliovirus vaccine, especially in older children. Here, we review the available evidence regarding the impact of IPV on mucosal immunity, and consider the implications of this evidence for the polio eradication endgame. We conclude that the implementation of IPV in both routine and supplementary immunization activities has the potential to play a key role in halting poliovirus transmission, and thereby hasten the eradication of polio.
引用
收藏
页码:1113 / 1123
页数:11
相关论文
共 50 条
  • [41] Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame
    Zipursky, Simona
    Patel, Manish
    Farrell, Margaret
    Gonzalez, Alejandro Ramirez
    Kachra, Tasleem
    Folly, Yann
    Kurji, Feyrouz
    Veira, Chantal Laroche
    Wootton, Emily
    Hampton, Lee M.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S15 - S23
  • [42] Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
    Tevi-Benissan, Carol
    Okeibunor, Joseph
    du Chatellier, Gael Maufras
    Assefa, Afework
    Biey, Joseph Nsiari-Muzenyi
    Cheikh, Dah
    Eshetu, Messeret
    Anya, Blanche-Philomene
    Dao, Halima
    Nasir, Yusuf
    Akanmori, Bartholomew Dicky
    Mihigo, Richard
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S66 - S75
  • [43] Intestinal mucosal immunity is unimportant for polio eradication: the failure of oral polio vaccination
    John, T. Jacob
    Dharmapalan, Dhanya
    Hirschhorn, Norbert
    INFECTIOUS DISEASES, 2024, 56 (08) : 669 - 677
  • [44] Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial
    Snider, Cynthia J.
    Zaman, Khalequ
    Wilkinson, Amanda L.
    Aziz, Asma Binte
    Yunus, Mohammad
    Haque, Warda
    Jones, Kathryn A. V.
    Wei, Ling
    Estivariz, Concepcion F.
    Konopka-Anstadt, Jennifer L.
    Mainou, Bernardo A.
    Patel, Jaymin C.
    Lickness, Jacquelyn S.
    Pallansch, Mark A.
    Wassilak, Steven G. F.
    Oberste, M. Steven
    Anand, Abhijeet
    VACCINE, 2023, 41 (41) : 6083 - 6092
  • [45] Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Tune 2?
    Resik, Sonia
    Tejeda, Alina
    Mach, Ondrej
    Fonseca, Magile
    Diaz, Manuel
    Alemany, Nilda
    Hung, Lai Heng
    Aleman, Yoan
    Mesa, Ileana
    Garcia, Gloria
    Sutter, Roland W.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 : S51 - S56
  • [46] Circulating vaccine-derived poliovirus and its implications for polio surveillance and eradication in Nigeria: A review of the literature
    Okonko, I. O.
    Ogun, A. A.
    Adedeji, A. O.
    Akanbi, O. A.
    Udeze, A. O.
    Motayo, O. B.
    SCIENTIFIC RESEARCH AND ESSAYS, 2009, 4 (05): : 398 - 418
  • [47] Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
    Brickley, Elizabeth B.
    Wieland-Alter, Wendy
    Connor, Ruth, I
    Ackerman, Margaret E.
    Boesch, Austin W.
    Arita, Minetaro
    Weldon, William C.
    O'Ryan, Miguel G.
    Bandyopadhyay, Ananda S.
    Wright, Peter F.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 : S42 - S50
  • [48] SHEDDING OF VIRULENT POLIOVIRUS REVERTANTS DURING IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE AFTER PRIOR IMMUNIZATION WITH INACTIVATED POLIO VACCINE
    ABRAHAM, R
    MINOR, P
    DUNN, G
    MODLIN, JF
    OGRA, PL
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (05): : 1105 - 1109
  • [49] Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel
    Swartz, T. A.
    Green, M. S.
    Handscher, R.
    Sofer, D.
    Cohen-Dar, M.
    Shohat, T.
    Habib, S.
    Barak, E.
    Dror, Z.
    Somekh, E.
    Peled-Leviathan, T.
    Yulzari, R.
    Libling, A.
    Mendelson, E.
    Shulman, L. M.
    VACCINE, 2008, 26 (08) : 1083 - 1090
  • [50] Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
    Xu, Jiawei
    Liu, Yang
    Qiu, Wei
    Li, Wenwen
    Hu, Xiaoxiao
    Li, Xia
    Fan, Qiang
    Tang, Wenge
    Wang, Yujie
    Wang, Qing
    Yao, Ning
    BMC INFECTIOUS DISEASES, 2024, 24 (01)